Dernières nouvelles
Information non disponible
- Denis-Langlois, May-LinaEmployéHôpital de l'Enfant-Jésus+1 418-525-4444, poste 67517may-lina.denis-langlois@crchudequebec.ulaval.ca
1401 18e Rue
G3.382
Québec, QC
Canada G1J 1Z4 - Gontier, ÉmilieEmployéHôpital de l'Enfant-Jésus+1 418-525-4444, poste 67529emilie.gontier@chudequebec.caemilie.gontier@crchudequebec.ulaval.ca
1401, 18e rue
G3.457
Québec, QC
Canada G1J 1Z4 - Hébert, YolaineEmployéHôpital de l'Enfant-Jésus+1 418-525-4444, poste 67515+1 418-649-5956yolaine.hebert@chudequebec.cayolaine.hebert@crchudequebec.ulaval.ca
1401, 18e Rue
G3.382
Québec, Québec
Canada G1J 1Z4 - Lacroix, ÉmilieEmployéHôpital de l'Enfant-Jésus+1 418-525-4444, poste 67311emilie.lacroix@crchudequebec.ulaval.ca
1401, 18e rue
G2.457
Québec, QC
Canada G1J 1Z4 - Lépine, Marie-ClaudeEmployéHôpital de l'Enfant-Jésus+1 418-525-4444, poste 67530marie-claude.lepine@crchudequebec.ulaval.ca
1401, 18e rue
G3.457
Québec, QC
Canada G1J 1Z4 - Nadeau, PhilippeEmployéHôpital de l'Enfant-Jésus+1 418-649-0252, poste 67324+1 418-649-5956philippe.nadeau@chudequebec.caphilippe.nadeau@crchudequebec.ulaval.ca
1401, 18e Rue
G2.466
Québec, Québec
Canada G1J 1Z4 - Tremblay, Marie-ClaudeEmployéHôpital de l'Enfant-Jésus+1 418-525-4444, poste 67519+1 418-649-5733Marie-Claude.Tremblay@crchudequebec.ulaval.ca
1401, 18e Rue
G3.382
Québec, Québec
Canada G1J 1Z4 - Tremblay, MichèleEmployéHôpital de l'Enfant-Jésus+1 418-525-4444, poste 67518+1 418-649-0252, poste 63115+1 418-649-5956michele.tremblay@chudequebec.camichele.tremblay@crchudequebec.ulaval.ca
1401, 18e Rue
G3.382
Québec, Québec
Canada G1J 1Z4 - Vallée, LindaEmployéHôpital de l'Enfant-Jésus+1 418-525-4444, poste 67516+1 418-649-5956linda.vallee@chudequebec.calinda.vallee@crchudequebec.ulaval.ca
1401, 18e Rue
G3.382
Québec, Québec
Canada G1J 1Z4
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma
Article de revueBlood, 2022.
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma
Article de revueBlood, 137 (5), 2021.
Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplantation-Eligible Patients
Article de revueBiol Blood Marrow Transplant, 25 (8), 2019.
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
Article de revueN Engl J Med, 379 (10), 2018.
Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial
Article de revueAnn Oncol, 29 (3), 2018.
Exercise Lowers Plasma Angiopoietin-Like 2 in Men with Post-Acute Coronary Syndrome
Article de revuePLoS One, 11 (10), 2016.
An open-label expanded-access trial of bendamustine in patients with rituximab-refractory indolent non-Hodgkin lymphoma or previously untreated chronic lymphocytic leukemia: BEND-ACT
Article de revueCurr Oncol, 22 (4), 2015.
Romidepsin used as monotherapy in sequence with allogeneic stem cell transplant in a patient with peripheral T-cell lymphoma
Article de revueCase Rep Hematol, 2014 , 2014.
Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma
Article de revueBiol Blood Marrow Transplant, 20 (11), 2014.
Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study
Article de revueJ Clin Oncol, 32 (17), 2014.